Showing 111 of 111on this page. Filters & sort apply to loaded results; URL updates for sharing.111 of 111 on this page
BioCardia announces FDA review completion of ongoing cell therapy for ...
BioCardia and StemCardia Announce Partnership to Deliver Cell-Gene ...
BioCardia
BCDA Insider Trading | BioCardia Buys and Sells
BioCardia Receives FDA Breakthrough Device Designation for CardiAMP ...
San Carlos, CA, USA - Feb 29, 2020: The BioCardia sign at the clinical ...
BioCardia and CellProthera Enhance Collaboration for Development of ...
BioCardia Files Pre-Submission for FDA Approval of Helix Catheter
BioCardia developing autologous and allogenic cardiovascular cell ...
BioCardia Launches Morph DNA Steerable Introducer Product Family ...
Master IGCSE Biology with Dr. Ibrahim's BioCardia
BioCardia (BCDA) Stock Price, News & Analysis
Buy BioCardia Inc. Stock – BCDA Stock Quote Today & Investment Insights ...
BioCardia Announces FDA Breakthrough Device Designation for CardiAMP ...
Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell ...
Bio Heart Biologica Logo Selective Sorting Vector, Biologica, Logo ...
Create Your Cardiology Logo — It’s Free to Try | LogoDesign.Net
BioCardia sets Q4 2025 for FDA and PMDA submissions for CardiAMP and ...
BioCardia Seeks Accelerated FDA Path for CardiAMP Cell Therapy in ...
BioCardia (BCDA) Gains FDA Nod for ARDS Cell Therapy Study
BioCardia eyes 2026 Japan approval for heart failure therapy
BioCardia - Crunchbase Company Profile & Funding
BioCardia Launches Innovative Morph DNA Steerable Introducer Family ...
BioCardia Shares FDA & PMDA Timeline for CardiAMP & Helix | Pienomial
BioCardia (BCDA) Fair Value DCF Calculator
BioCardia (BCDA) Stock Price & Overview
Biocardia Pauses Trial of Innovative Stem Cell Therapy
BioCardia outlines regulatory milestones and targets FDA and PMDA ...
BioCardia CardiAmp trial passes safety analysis - Cardiovascular News
BioCardia Starts CardiAMP HF II Patient Enrollment at Emory
BioCardia CEO and Key Executive Team | Craft.co
BioCardia Investors Await Critical Quarterly Update
BioCardia Submits FDA Application for New Steerable Cardiovascular ...
BioCardia submits 510(k) approval for Morph DNA steerable introducer ...
Biocardia 2025 Q3 Earnings Narrowed Losses and Regulatory Progress
Opko Health gets in on BioCardia after merger with Tiger X Medical ...
BioCardia Updates on CardiAMP® and Helix™ Regulatory Timelines
Biocardia 2024 Q2 Earnings Misses Targets as Revenue Declines 93%
BioCardia Seeks Approval in Japan for Cell Therapy for Ischemic Heart ...
Biocardia 2025 Q3 Earnings Narrowed Losses Amid Regulatory Progress
BioCardia finds alternative funding solution | BioPharma Dive
Cardiology logo vector | Premium AI-generated vector
BioCardia Announces First UW Patient in Phase 3 CardiAMP HF II | BCDA ...
BioCardia Completes FDA Pre-Submission for Helix Transendocardial ...
BioCardia Announces FDA Completes Review of Proposed Adaptive ...
$BCDA BioCardia Inside Buying & Approval anticipation : r/pennystocks
BioCardia Inc (Nasdaq: BCDA) Achieves Significant FDA Clearance for ...
BioCardia Announces New Center for Medicare and Medicaid Services ...
BioCardia Announces US Patent on Imaging System for Targeting Cardiac ...
BioCardia Announces Pricing of $10 Million Public Offering - Biotech Today
CellProthera and BioCardia announce successful results from ...
Premium Vector | Cardiology logo
Biocardia Helix Biotherapeutic Delivery System
BIOCARDIA INC.NEW DL-,001 Aktie - Realtime-Kurse & Charts - A2PLXH ...
**Cell Therapy**: BioCardia Earnings Call Reveals Breakthrough Results ...
BioCardia announces long-term partnership with StemCardia
Limited Release of BioCardia AVANCE™ Steerable CV Catheter Introducer ...
BioCardia Completes Phase III Clinical Trial of Autologous Stem Cell ...
BioCardia Inc (BCDA) - Product Pipeline Analysis, 2025 Update
BioCardia CEO Altman Peter buys 400 shares at $1.75/share on 2025-08-12.
Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for ...
BioCardia, Inc. | MSCRF
臨牀階段再生醫學公司：BioCardia, Inc.(BCDA) – 美股投資指南
BioCardia®, Inc. Announces Two Presentations Related to CardiAMP Cell ...
BioCardia, Inc. | LinkedIn
BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript
Diagnosti... - Diagnostic and Interventional Cardiology - DAIC
BioCardia's Q4 2025 Regulatory Milestones and Their Market Implications
EnMasse Industrial Design LLC | Mountain View, California | Product ...
BioCardia, Inc. on LinkedIn: #transendocardialdelivery #celltherapy # ...
BioCardia's $12M Raise: A Strategic Move to Accelerate Regenerative ...
BioCardia's Q3 2025 Earnings Call: Contradictions Emerge on Japan ...
Transactions » Titan Partners
BioCardia, Inc. Q4 2025 Earnings Call Summary
Congratulations to the team led by Dr. Anderson for a successful first ...
BioCardia’s CardiAMP HF II Phase 3 Trial: First Patient Enrolled at ...
BioCardia's CardiAMP Cell Therapy for Heart Failure Receives FDA Review ...
BioCardia's CardiAMP Cell Therapy: A Regenerative Breakthrough for ...
BioCardia, Nasdaq:BCDA | Stock Price, Short Interest, Options, News ...
BioCardia’s Funding Fuels Progress For Its Heart Therapy - Finimize
BioCardia心衰竭細胞療法獲DSMB正面評估 - ss future
BioCardia, Inc. - AnnualReports.com
